Christine J. Guico-Pabia - Jan 28, 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRV)

Role
Chief Medical Officer
Signature
/s/ J. Christopher Naftzger, power of attorney
Stock symbol
NBRV
Transactions as of
Jan 28, 2022
Transactions value $
$0
Form type
4
Date filed
2/1/2022, 05:40 PM
Previous filing
Nov 1, 2021
Next filing
Aug 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBRV Share Options Award $0 +71.5K $0.00 71.5K Jan 28, 2022 Ordinary Shares 71.5K $0.45 Direct F1, F2
transaction NBRV Restricted Stock Units Award $0 +35.7K $0.00 35.7K Jan 28, 2022 Ordinary Shares 35.7K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
F2 Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
F3 The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date.
F4 Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.